Search Results - "Assaf, Zoe J"

Personalized Detection of Circulating Tumor DNA Antedates Breast Cancer Metastatic Recurrence by Coombes, Raoul Charles, Page, Karen, Salari, Raheleh, Hastings, Robert K, Armstrong, Anne, Ahmed, Samreen, Ali, Simak, Cleator, Susan, Kenny, Laura, Stebbing, Justin, Rutherford, Mark, Sethi, Himanshu, Boydell, Anna, Swenerton, Ryan, Fernandez-Garcia, Daniel, Gleason, Kelly L T, Goddard, Katie, Guttery, David S, Assaf, Zoe J, Wu, Hsin-Ta, Natarajan, Prashanthi, Moore, David A, Primrose, Lindsay, Dashner, Scott, Tin, Antony S, Balcioglu, Mustafa, Srinivasan, Ramya, Shchegrova, Svetlana V, Olson, Alexander, Hafez, Dina, Billings, Paul, Aleshin, Alexey, Rehman, Farah, Toghill, Bradley J, Hills, Allison, Louie, Maggie C, Lin, Cheng-Ho Jimmy, Zimmermann, Bernhard G, Shaw, Jaqueline A

“…Up to 30% of patients with breast cancer relapse after primary treatment. There are no sensitive and reliable tests to monitor these patients and detect…”
Get full text

Circulating Tumor DNA Dynamics Reveal KRAS G12C Mutation Heterogeneity and Response to Treatment with the KRAS G12C Inhibitor Divarasib in Solid Tumors by Choi, Yoonha, Dharia, Neekesh V, Jun, Tomi, Chang, Julie, Royer-Joo, Stephanie, Yau, Kenneth K, Assaf, Zoe J, Aimi, Junko, Sivakumar, Smruthy, Montesion, Meagan, Sacher, Adrian, LoRusso, Patricia, Desai, Jayesh, Schutzman, Jennifer L, Shi, Zhen

“…To inform prognosis, treatment response, disease biology, and KRAS G12C mutation heterogeneity, we conducted exploratory circulating tumor DNA (ctDNA)…”
Get full text

Circulating Tumor DNA Assessment for Treatment Monitoring Adds Value to PSA in Metastatic Castration-Resistant Prostate Cancer by Sweeney, Christopher J, Petry, Russell, Xu, Chang, Childress, Merrida, He, Jie, Fabrizio, David, Gjoerup, Ole, Morley, Samantha, Catlett, Timothy, Assaf, Zoe J, Yuen, Kobe, Wongchenko, Matthew, Shah, Kalpit, Gupta, Pratyush, Hegde, Priti, Pasquina, Lincoln W, Mariathasan, Sanjeev, Graf, Ryon P, Powles, Thomas

“…Enzalutamide after abiraterone progression is commonly used in metastatic castration-resistant prostate cancer despite a low rate of clinical benefit…”
Get full text

The population genetics of drug resistance evolution in natural populations of viral, bacterial and eukaryotic pathogens by Wilson, Benjamin A., Garud, Nandita R., Feder, Alison F., Assaf, Zoe J., Pennings, Pleuni S.

“…Drug resistance is a costly consequence of pathogen evolution and a major concern in public health. In this review, we show how population genetics can be used…”
Get full text

Genome and Exome-Wide Studies Reveal Potential Predictive Efficacy Markers for Venetoclax and Rituximab (VenR) in Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL): Subgroup Analyses of the Murano Trial by Kater, Arnon P, Wu, Jenny Qun, Dubois, Julie, Bolen, Christopher R, Assaf, Zoe J, Hillmen, Peter, Eichhorst, Barbara F., Eldering, Eric F, Kipps, Thomas J., Langerak, Anton W, Mellink, Clemens, Van Der Kevie-Kersemaekers, Anne-Marie, Owen, Carolyn, Chyla, Brenda J, Punnoose, Elizabeth A, Wang, Jue, Lefebure, Marcus, Boyer, Michelle, Humphrey, Kathryn, Jiang, Yanwen, Seymour, John F.

“…The first two authors contributed equally. Introduction: VenR (2 years of Ven, plus R during the first 6 months) improved progression-free/overall survival…”
Get full text